Bioactive Compounds Against SARS-CoV-2 1st Edition

Bioactive Compounds Against SARS-CoV-2 — 1st Edition by delivers a timely, authoritative exploration of antiviral agents and natural Books investigated for activity against SARS-CoV-2 and COVID-19. Capturing global urgency and cutting-edge science, this book immediately draws in researchers, clinicians, and public-health professionals seeking evidence-based insights into antiviral discovery and development.

Inside, readers will find clear, well-organized discussions of screening methodologies, molecular mechanisms, pharmacology, and preclinical findings. The volume balances rigorous analysis of synthetic and natural bioactive compounds with practical perspectives on translational research, molecular docking, in vitro and in vivo evaluation, and strategies for confronting emerging SARS-CoV-2 variants. Case studies and comparative reviews make complex data accessible for academic labs, pharmaceutical teams, and policy advisors across North America, Europe, Asia, Africa, and Latin America.

What sets this 1st edition apart is its practical orientation: succinct summaries, critical appraisals of current literature, and forward-looking commentary on drug discovery pipelines and public-health implications. Whether you’re a doctoral student, medicinal chemist, infectious-disease specialist, or health policymaker, this book equips you with the context and scientific tools to navigate antiviral research in a post-pandemic landscape.

Authoritatively written yet approachable, Bioactive Compounds Against SARS-CoV-2 is an essential reference for anyone engaged in COVID-19 research or antiviral strategy development. Add this indispensable resource to your library today to stay informed on global advances in antiviral compounds and therapeutic innovation.

Note: eBooks do not include supplementary materials such as CDs, access codes, etc.